Lake Street Capital Markets LLC
05/28/2026 | Press release | Distributed by Public on 05/28/2026 10:00
Aligos Therapeutics, Inc. (ALGS) - Initiation of Coverage
Lake Street Capital Markets Analyst, Daniel Brims, initiated coverage of Aligos Therapeutics, Inc. with a BUY rating and price target of $45 (ALGS-$45). Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
Want to stay up-to-date with the latest at Lake Street? Subscribe to our mailing list!
NameEmail Address
Thanks for joining our mailing list.
Oops! Something went wrong while submitting the form.
Lake Street Capital Markets LLC published this content on May 28, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 28, 2026 at 16:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]